-
Active Watch List: Gilead Sciences Inc. (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Sirius XM Holdings (NASDAQ:SIRI), Post Holdings (NYSE:POST), Ethan Allen Interiors (NYSE:ETH)
On Wednesday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $106.39. Company’s sales growth for last 5 years was 28.80% and EPS growth for next 5 years is recorded as 13.30%. Gilead Sciences, Inc. (NASDAQ:GILD) announced that its corporate presentation webcast from the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas.…
-
Investors Watch List: Rexahn Pharmaceuticals (NYSEMKT:RNN), MannKind Corp. (NASDAQ:MNKD), Kaman Corporation (NYSE:KAMN), Signal Genetics (NASDAQ:SGNL), Embraer SA (NYSE:ERJ)
On Monday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.72. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on April 21, 2015, declared that it presented preclinical data on Supinoxin(TM) (RX-5902) at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. This presentation entitled, “Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)…
-
Morning Watch List: Rexahn Pharmaceuticals (NYSEMKT:RNN), General Motors Company (NYSE:GM), Isis Pharmaceuticals (NASDAQ:ISIS), Google Inc (NASDAQ:GOOGL), Solar Capital (NASDAQ:SLRC)
On Wednesday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.71. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on April 21, 2015, declared that it presented preclinical data on Supinoxin(TM) (RX-5902) at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. This presentation entitled, “Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)…
-
Hot Alert: Rexahn Pharmaceuticals (NYSEMKT:RNN), Lennar Corp. (NYSE:LEN), King Digital Entertainment plc (NYSE:KING), WSFS Financial Corp. (NASDAQ:WSFS), Systemax Inc. (NYSE:SYX)
On Thursday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.70. On March 10, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) provided financial results for the year ending December 31, 2014. Rexahn’s cash and investments totaled $32.7 million as of December 31, 2014, compared to $19.0 million as of December 31, 2013. The increase of $13.7 million was…
-
Stocks Getting Investor’s Attention: Rexahn Pharmaceuticals (NYSEMKT:RNN), eBay Inc. (NASDAQ:EBAY), Gilat Satellite Networks (NASDAQ:GILT), Wal-Mart Stores (NYSE:WMT), Yelp (NYSE:YELP)
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s Director of Business Development Vikas Sharma, Ph.D., presented at the BIO-Europe Spring® 2015 Conference in Paris, France on Tuesday, March 10, 2015 at 2:15 PM (Central European Time). On Tuesday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.73. On March 2, it was reported that, EBay Inc. (NASDAQ:EBAY)’s PayPal, agreed…
-
5 Stock in Different Moves: Valero Energy Corporation (NYSE:VLO), Plug Power (NASDAQ:PLUG), Restoration Hardware (NYSE:RH), The Community Financial (NASDAQ:TCFC), Rexahn Pharmaceuticals (NYSEMKT:RNN)
Valero Energy Corporation (NYSE:VLO) experienced a 1.97 percent bump in its stock price after the company announced that CEO Joe Gorder would be presenting at the Credit Suisse Energy Summit later this month, WallStreet Scope reported Wednesday. Valero’s stock is currently trading at around $55 per share on Wednesday morning. On Wednesday shares of Valero…
-
Investors Are Eying: Johnson & Johnson (NYSE:JNJ), General Electric Company (NYSE:GE), Rexahn Pharmaceuticals (NYSEMKT:RNN), Twitter Inc (NYSE:TWTR), Kindred Healthcare Inc. (NYSE:KND)
The decision as to whether Boston Scientific should pay competitor Johnson & Johnson (NYSE:JNJ) $7.2 billion — nearly all of the Marlborough company’s revenues last year — is now in the hands of a federal judge. In total, the court hearing lasted about two months since it began last November. U.S. District Judge Richard Sullivan…
-
Top Stocks: Flamel Technologies SA (NASDAQ:FLML), Rexahn Pharmaceuticals (NYSEMKT:RNN), NiSource Inc. (NYSE:NI), Energy Recovery (NASDAQ:ERII), Trinseo SA (NYSE:TSE)
Flamel Technologies (NASDAQ:FLML) learned the U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s New Drug Application (NDA) for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. On Wednesday shares of Flamel Technologies SA (NASDAQ:FLML) closed at $11.50. Company’s sales growth for last 5 years was -10.30%. Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) Director…
-
Investors Are Eying: Rexahn Pharmaceuticals (NYSEMKT:RNN), Staples (NASDAQ:SPLS), Level 3 Communications (NYSE:LVLT), YuMe (NYSE:YUME), Ares Management, L.P. (NYSE:ARES)
Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 5,376,283 shares, a drop of 1.8% from the December 15th total of 5,475,483 shares, American Banking & Market News reports. On Tuesday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at…
-
Moving Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Morgan Stanley (NYSE:MS), Biogen Idec Inc. (NASDAQ:BIIB), Symetra Financial Corporation (NYSE:SYA), Globalstar Inc. (NYSEMKT:GSAT)
Rexahn Pharmaceuticals (NYSEMKT:RNN) CFO Tae Heum Jeong sold 317,272 shares of the company’s stock on the open market in a transaction dated Monday, January 12th. The stock was sold at an average price of $0.91, for a total transaction of $288,717.52. Following the transaction, the chief financial officer now directly owns 505,000 shares in the…